Elekta has received 510(k) clearance from the US Food and Drug Administration (FDA) to include refractory, intractable mesial temporal lobe epilepsy (MTLE) in adults as an approved indication for Leksell Gamma Knife-radiosurgery system. The Gamma Knife directs 192 beams of gamma radiation with high precision to the area of the brain that is causing the seizures. The system has been used globally since 1968 and has treated nearly two million patients.
|
Published July 23, 2025
Elekta receives FDA approval for Gamma Knife for epilepsy
Notes
VibroSense Dynamics announces delayed deliveries to China
Acarix reports strong growth in Q3 2025
20 percent weight loss for Eli Lilly's amylin agonist
Stable outlook for AstraZeneca
Camurus lowers full-year forecast
Thor Medical signs supply agreement with Telix
FluoGuide strengthens clinical development management
NEWSLETTER
Upcoming events
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
How European companies can succeed in the Chinese deal market
FDA concerns delay Xspray Pharma's Dasynoc approval again
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
